-

06:23:24 PM

BRTX Stock News

BRTX - BioRestorative Therapies Inc

03/13/23 7:00 AM

Nasdaq : BRTX

fda approvallow float

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies,

RHEA-AI

very positive

03/07/23 6:30 AM

Nasdaq : BRTX

conferenceslow float

BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023

BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate at the Roth 35 th Annual

RHEA-AI

neutral

03/02/23 7:30 AM

Nasdaq : BRTX

low float

BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:

RHEA-AI

very positive

02/08/23 9:00 AM

Nasdaq : BRTX

low float

BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the

RHEA-AI

neutral

12/06/22 7:00 AM

Nasdaq : BRTX

low float

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a

RHEA-AI

positive

12/05/22 7:00 AM

Nasdaq : BRTX

low float

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. (“BioRestorative” or the “Company” ) (NASDAQ : BRTX ), a clinical stage company focused on stem cell-based

RHEA-AI

very positive

11/29/22 11:20 AM

Nasdaq : BRTX

conferenceslow float

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

via InvestorWire – BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK Capital Disruptive Growth Conference in New York City. Event RHK Capital Disruptive Growth Conference

RHEA-AI

neutral

11/16/22 8:56 AM

Nasdaq : BRTX

conferenceslow float

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate on December 5-6, 2022 at the RHK

RHEA-AI

neutral

10/20/22 9:30 AM

Nasdaq : BRTX

low float

BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show

BioRestorative Therapies, Inc. (the “Company” or “ BioRestorative ”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that its CEO, Lance Alstodt, will be interviewed on Famela and Friends Talk Radio

RHEA-AI

neutral

09/28/22 7:00 AM

Nasdaq : BRTX

conferenceslow float

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be presenting at the Dawson James Securities 7 th Annual

RHEA-AI

neutral